Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Targeted Treatment of Hematological Malignancy
share announcement

Targeted Treatment of Hematological Malignancy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 30 August 2025 | Viewed by 4134

Special Issue Editors

Dr. Laura Eadie

E-Mail Website
Guest Editor
Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA 5000, Australia
Interests: acute lymphoblastic leukemia; drug resistance; pre-clinical modelling; genomic analyses; precision medicine
Dr. Chloe A.L. Thompson-Peach

E-Mail
Guest Editor
1. Blood Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
2. Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia
Interests: myelofibrosis; myeloproliferative neoplasms; acute myeloid leukaemia; mutation-specific therapies; immunotherapy; CAR-T cell therapy
Dr. Elyse C. Page

E-Mail Website
Guest Editor
1. Blood Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
2. Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia
Interests: acute lymphoblastic leukemia; gene therapy; murine models; genomic predisposition; precision medicine
Prof. Dr. Deborah White

E-Mail Website
Guest Editor
Blood Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
Interests: acute lymphoblastic leukemia; pre-clinical modelling; genomic analyses; precision medicine; functional genomics; microbiome

Special Issue Information

Dear Colleagues,

Our Special Issue on the Targeted Treatment of Hematological Malignancy aims to provide a comprehensive overview of the latest advancements and emerging trends in the field of hematology. The collection of articles in this Special Issue will focus on areas, such as novel targeted therapies and their efficacy in different malignancies, immunotherapeutic approaches for hematological malignancies, personalized treatment strategies, as well as diagnostic tools for assessing treatment responses.

We welcome original research articles, comprehensive reviews, and meta-analyses that provide valuable insights into the targeted treatment of hematological malignancies. However, please note that this Special Issue will not consider mini-reviews or case reports.

This Special Issue presents an excellent opportunity for researchers and clinicians to contribute to advanced targeted treatment options for hematological malignancies. We anticipate that the collection of articles in this Special Issue will provide valuable knowledge and pave the way for future breakthroughs in hematology.

We look forward to receiving your contributions and thank you for your support.

Dr. Laura Eadie
Dr. Chloe A.L. Thompson-Peach
Dr. Elyse C. Page
Prof. Dr. Deborah White
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • leukemia
  • lymphoma
  • multiple myeloma
  • myelodysplastic syndromes
  • chronic myeloid leukemia
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • non-Hodgkin lymphoma
  • Hodgkin lymphoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 431 KiB  
Article
Metabolic Sequelae and Quality of Life in Early Post-Treatment Period in Adolescents with Hodgkin Lymphoma
by Ines Pranjić, Sara Sila, Sara Lulić Kujundžić, Mateja Dodig, Anna Vestergaard Larsen and Izabela Kranjčec
J. Clin. Med. 2025, 14(2), 375; https://doi.org/10.3390/jcm14020375 - 9 Jan 2025
Viewed by 722
Abstract
Background/Objectives: The long-term consequences of intensive treatment for Hodgkin lymphoma (HL), including metabolic syndrome (MetS) and cardiovascular diseases, but also deteriorated quality of life (QoL), are present in many survivors of childhood HL. Methods: Adolescents and young adults diagnosed with HL [...] Read more.
Background/Objectives: The long-term consequences of intensive treatment for Hodgkin lymphoma (HL), including metabolic syndrome (MetS) and cardiovascular diseases, but also deteriorated quality of life (QoL), are present in many survivors of childhood HL. Methods: Adolescents and young adults diagnosed with HL who continued the follow-up after successful treatment for HL were included. Anthropometric parameters, body composition, laboratory data, blood pressure values, compliance to the Mediterranean diet (MD), QoL and lifestyle habits were evaluated at the follow-up. Available data were also extracted retrospectively at the time of diagnosis. The primary objective was to determine metabolic sequelae in the early post-treatment period in adolescents treated for HL. Additionally, QoL and compliance with MD were explored, and the correlation of MetS with QoL was investigated. Results: Sixty percent of patients had at least one risk factor for metabolic syndrome, with obesity/abdominal obesity, high blood pressure and low HDL being most commonly observed, present in 66.7%, 44.4% and 44.4% of patients, respectively. The number of obese patients increased from 6.3% at the diagnosis to 31.3% at the follow-up. The majority of patients (53.3%) had low adherence to the MD. Participants had comparable quality-of-life domains to those of the healthy population at the follow-up. The physical health domain of QoL was positively correlated with compliance to the MD in young adults (r = 0.8, p = 0.032) and negatively correlated with obesity/overweight in adolescents (r = −0.85, p = 0.008). Conclusions: Healthy lifestyle choices can impact not only the metabolic health of survivors but also their quality of life, and therefore should be encouraged in these patients. Full article
(This article belongs to the Special Issue Targeted Treatment of Hematological Malignancy)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

16 pages, 736 KiB  
Review
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma
by Athanasios Liaskas, Maria N. Dimopoulou, Alexia Piperidou, Maria K. Angelopoulou and Theodoros P. Vassilakopoulos
J. Clin. Med. 2025, 14(4), 1191; https://doi.org/10.3390/jcm14041191 - 11 Feb 2025
Viewed by 903
Abstract
Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare, aggressive B-cell lymphoma, sharing common features with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). PMLBCL is usually cured with single-hit immunochemotherapy in the first-line setting. Relapses tend to be aggressive and may [...] Read more.
Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare, aggressive B-cell lymphoma, sharing common features with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). PMLBCL is usually cured with single-hit immunochemotherapy in the first-line setting. Relapses tend to be aggressive and may be unresponsive to conventional chemotherapy. Autologous stem cell transplant (ASCT) remains a viable option for chemosensitive patients; nevertheless, targeted therapies appear to be highly promising. Checkpoint inhibitors (CPIs) have already transformed the course of relapse/refractory disease, while CD-19-directed Chimeric Antigen Receptor (CAR) T-cell therapy may produce remarkably favorable outcomes. The exact position of CAR T-cells and CPIs in the treatment algorithm, along with the role of radiotherapy and ASCT, remains to be precisely determined. In the current review, we aim to present the recent research on targeted agents in PMLBCL and define their sequencing within the treatment algorithm, mainly in the relapse/refractory setting. Full article
(This article belongs to the Special Issue Targeted Treatment of Hematological Malignancy)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

25 pages, 1337 KiB  
Systematic Review
Applications of Artificial Intelligence in Acute Promyelocytic Leukemia: An Avenue of Opportunities? A Systematic Review
by Mihnea-Alexandru Găman, Monica Dugăeşescu and Dragoş Claudiu Popescu
J. Clin. Med. 2025, 14(5), 1670; https://doi.org/10.3390/jcm14051670 - 1 Mar 2025
Cited by 1 | Viewed by 905
Abstract
Background. Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia defined by the presence of a genetic abnormality, namely the PML::RARA gene fusion, as the result of a reciprocal balanced translocation between chromosome 17 and chromosome 15. APL is a [...] Read more.
Background. Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia defined by the presence of a genetic abnormality, namely the PML::RARA gene fusion, as the result of a reciprocal balanced translocation between chromosome 17 and chromosome 15. APL is a veritable emergency in hematology due to the risk of early death and coagulopathy if left untreated; thus, a rapid diagnosis is needed in this hematological malignancy. Needless to say, cytogenetic and molecular biology techniques, i.e., fluorescent in situ hybridization (FISH) and polymerase chain reaction (PCR), are essential in the diagnosis and management of patients diagnosed with APL. In recent years, the use of artificial intelligence (AI) and its brances, machine learning (ML), and deep learning (DL) in the field of medicine, including hematology, has brought to light new avenues for research in the fields of blood cancers. However, to our knowledge, there is no comprehensive evaluation of the potential applications of AI, ML, and DL in APL. Thus, the aim of the current publication was to evaluate the prospective uses of these novel technologies in APL. Methods. We conducted a comprehensive literature search in PubMed/MEDLINE, SCOPUS, and Web of Science and identified 20 manuscripts eligible for the qualitative analysis. Results. The included publications highlight the potential applications of ML, DL, and other AI branches in the diagnosis, evaluation, and management of APL. The examined AI models were based on the use of routine biological parameters, cytomorphology, flow-cytometry and/or OMICS, and demonstrated excellent performance metrics: sensitivity, specificity, accuracy, AUROC, and others. Conclusions. AI can emerge as a relevant tool in the evaluation of APL cases and potentially contribute to more rapid screening and identification of this hematological emergency. Full article
(This article belongs to the Special Issue Targeted Treatment of Hematological Malignancy)
►▼ Show Figures

Figure 1

16 pages, 1775 KiB  
Systematic Review
Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review
by Maria Dimou, Angelo Vacca, Silvia Sánchez-Ramón, Ewa Karakulska-Prystupiuk, Vikte Lionikaite, Csaba Siffel, Colin Anderson-Smits and Marta Kamieniak
J. Clin. Med. 2025, 14(4), 1203; https://doi.org/10.3390/jcm14041203 - 12 Feb 2025
Viewed by 1093
Abstract
Background: Secondary immunodeficiency disease (SID) is a complex, heterogeneous condition that occurs when extrinsic factors weaken the immune system. Expert consensus guidelines recommend immunoglobulin replacement therapy to manage immunoglobulin G (IgG) levels and mitigate severe, recurrent, and persistent infections. Hyaluronidase-facilitated subcutaneous immunoglobulin [...] Read more.
Background: Secondary immunodeficiency disease (SID) is a complex, heterogeneous condition that occurs when extrinsic factors weaken the immune system. Expert consensus guidelines recommend immunoglobulin replacement therapy to manage immunoglobulin G (IgG) levels and mitigate severe, recurrent, and persistent infections. Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% is a dual-vial unit of IgG and recombinant human hyaluronidase; the latter enables absorption of higher volumes of IgG than conventional subcutaneous therapies. Methods: For this systematic literature review, Embase, MEDLINE®, and the Cochrane Library were searched on 9 August 2023, with supplemental congress searches. Results: Eight studies fulfilled the inclusion criteria, reporting real-world evidence of the clinical effectiveness, safety, and tolerability of fSCIG 10% in 183 patients with SID in Europe from September 2014 to August 2021. The potential causes of SID were primarily hematological malignancies, most commonly chronic lymphocytic leukemia. Treatment was typically administered at 4-week or 3-week intervals, with doses of approximately 0.4 g/kg/month. Infections were rare during follow-up, with numerical reductions observed after fSCIG 10% treatment initiation compared with the period before initiation. Adverse reactions, including local infusion site reactions, and tolerability events were uncommon. Conclusions: Given the recency of fSCIG 10% use in patients with SID, there are opportunities for future research to better understand survival and patient-reported outcomes after receiving this treatment. Despite SID heterogeneity, this study demonstrates the feasibility of fSCIG 10% treatment for this condition. Full article
(This article belongs to the Special Issue Targeted Treatment of Hematological Malignancy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop